$PHVS
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Healthcare
Sector
Biotechnology
Industry
Berndt Axel Edvard Modig
CEO
108
Employees
$33.95
Current Price
$1.63B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 9 | $4,611,044.87 | 130,872 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 13 | $5,291,590.09 | 150,472 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 5 | 17 | $5,455,388.17 | 155,733 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 11 | 27 | $7,494,788.42 | 223,770 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 11 | 51 | $12,525,933.09 | 392,395 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Apr 22, 2026 | Schikan Johannes Gerardus Christiaan Petrus Director | Sale | 7,000 | $30.05 | $210,378.70 | View Details |
| Apr 22, 2026 | Lesage Anne Chief Early Development | Sale | 500 | $30.00 | $15,000.00 | View Details |
| Apr 22, 2026 | Lesage Anne Chief Early Development | Sale | 7,000 | $30.05 | $210,357.70 | View Details |
| Apr 22, 2026 | Lesage Anne Chief Early Development | Sale | 7,000 | $30.05 | $210,361.90 | View Details |
| Apr 23, 2026 | Lesage Anne Chief Early Development | Sale | 100 | $30.03 | $3,003.00 | View Details |
| Apr 23, 2026 | Lesage Anne Chief Early Development | Sale | 100 | $30.03 | $3,003.00 | View Details |
| Apr 22, 2026 | Lu Peng Chief Medical Officer | Sale | 7,001 | $30.05 | $210,401.75 | View Details |
| Apr 23, 2026 | Lu Peng Chief Medical Officer | Sale | 100 | $30.03 | $3,003.00 | View Details |
| Apr 16, 2026 | Modig Berndt Director | Sale | 2,292 | $28.60 | $65,558.53 | View Details |
| Apr 9, 2026 | Modig Berndt Director | Sale | 200 | $28.41 | $5,683.00 | View Details |
| Apr 9, 2026 | Modig Berndt Director | Sale | 23,133 | $27.74 | $641,598.38 | View Details |
Showing 41โ51 of 51 transactions
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$0.71
ActualN/A
Revenue
EstimatedN/A
ActualN/A